Literature DB >> 22362958

Alloimmune neonatal neutropenia and neonatal isoerythrolysis in a Thoroughbred colt.

David M Wong1, Cody J Alcott, Sandra K Clark, Douglas E Jones, Phyllis G Fisher, Brett A Sponseller.   

Abstract

A 3-day-old Thoroughbred colt was originally presented for treatment of neonatal isoerythrolysis, which was treated with a blood transfusion. However, persistent neutropenia was observed despite the absence of detectable infection. Subsequently, a granulocyte agglutination test was performed by incubating the colt's neutrophils with the mare's serum; results were positive, leading to a clinical diagnosis of alloimmune neonatal neutropenia. The diagnosis was further supported via flow cytometric analysis. The colt was hospitalized and treated prophylactically with antimicrobials and 4 separate doses of recombinant human granulocyte colony-stimulating factor (rhG-CSF; 1.4-3.5 µg/kg, subcutaneously) in attempts to maintain the neutrophil count within reference intervals over a 4-week period. The colt's neutrophil count increased after administration of rhG-CSF and eventually stabilized within reference intervals by day 20. The colt maintained normal neutrophil counts after discharge and was reportedly healthy at 6 months of age. Alloimmune neonatal neutropenia should be considered in foals with persistent neutropenia in the absence of infection. Alloimmune neonatal neutropenia can be treated with prophylactic antimicrobials combined with rhG-CSF with a favorable outcome.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22362958     DOI: 10.1177/1040638711416850

Source DB:  PubMed          Journal:  J Vet Diagn Invest        ISSN: 1040-6387            Impact factor:   1.279


  1 in total

1.  Effects of low-dose G-CSF formulation on hematology in healthy horses after long-distance transportation.

Authors:  Yoshiro Endo; Seiji Hobo; Kenji Korosue; Kenji Ootsuka; Akira Kitauchi; Risa Kikkawa; Yuichi Hidaka; Mitsuyoshi Hagio; Nao Tsuzuki
Journal:  J Vet Med Sci       Date:  2015-01-19       Impact factor: 1.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.